| | 871026-44-7 Basic information More.. |
| Product Name: | TAK-285 | | Synonyms: | TAK-285;TAK-285(TAK 285);N-[2-[4-[[3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide;N-(2-(4-(3-Chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)e;CS-255;Butanamide, N-[2-[4-[[3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl]amino]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methyl-;TAK-285 USP/EP/BP;TAK-285, 10 mM in DMSO | | CAS: | 871026-44-7 | | MF: | C26H25ClF3N5O3 | | MW: | 547.96 | | EINECS: | 1533716-785-6 | | Mol File: | 871026-44-7.mol |  |
Use
TAK-285 is a novel dual HER2 and EGFR inhibitor with IC50 of 17 nM and 23 nM, respectively.
- TAK-285
-
- US $34.00-126.00 / mg
- 2025-07-12
- CAS:871026-44-7
- Min. Order:
- Purity: 99.73%
- Supply Ability: 10g
|
|
871026-44-7
Recommend Suppliers |
|